摘要
目的研究非小细胞肺癌(NSCLC)患者肿瘤组织和癌旁组织中IL-33的表达情况。方法采用实时荧光定量PCR(qRT-PCR)检测61例NSCLC患者的肿瘤组织和癌旁组织中IL-33 mRNA的表达水平,再用免疫组织化学染色进一步检测12例不同组织学类型的NSCLC石蜡标本中IL-33的蛋白定位与表达,分析其与肺癌患者临床病理参数、总生存(OS)之间的关系。结果 IL-33 mRNA在肺癌组织中的表达量明显低于癌旁组织,免疫组织化学染色结果表明IL-33蛋白定位于细胞核,并在肺癌组织中低表达。此外,IL-33在肺癌组织中的表达与肺癌病理类型有关,与患者临床病理特征年龄、性别、吸烟史、病理分级和临床分期等均无关;Kaplan-Meier生存曲线分析表明,IL-33 mRNA表达水平与术后生存时间显著正相关。结论 IL-33可能在肺癌的发生发展以及靶向治疗中发挥重要作用。
Objective To investigate the expression of interleukin 33( IL-33) in cancer and adjacent non-cancerous tissues from patients with non-small cell lung cancer( NSCLC). Methods Real-time quantitative PCR was performed to detect the mRNA expression of IL-33 in 61 pairs of cancerous and adjacent non-cancerous tissues. In addition,immunohistochemistry was used to evaluate the expression and location of IL-33 on paraffin sections in selected 12 cases with different pathological types,to analyze the correlation of IL-33 expression with clinicopathological variables and overall survival. Results The expression of IL-33 mRNA in cancer tissues was significantly lower than that in adjacent non-cancerous tissues. The immunohistochemical results showed that IL-33 protein was mainly localized in the nucleus, and was obviously down-regulated in NSCLC. Besides,the expression of IL-33 was associated with histological type,but was not associated with age,gender,smoking history,differentiation status and pathological TNM stage. According to the Kaplan-Meier analysis,the expression of IL-33 mRNA was evidently associated with post-operative overall survival of patients suffering from NSCLC. Conclusion IL-33 may play an important role in the development of NSCLC and the targeted therapy.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2016年第6期808-811,共4页
Chinese Journal of Cellular and Molecular Immunology
基金
国家自然科学基金(81273208)
国家自然科学基金海外及港澳学者合作研究基金(31428005)
江苏省科技厅江苏省科研型企业技术创新基金(BC2012093)